Radiopharm Theranostics Ltd has released a press release.
RAD 301 receives FDA Orphan Drug Designation
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Agreement with TerThera to supply Terbium-161 isotope
- Radiopharm to acquire Pharma15 Corporation
- Appendix 4D and Half Year Report
- Radiopharm Theranostics initiates process for Nasdaq listing
- aVb6 Integrin (RAD301) IND approval for Phase 1 trial
Later from Radiopharm Theranostics
- FDA Pre-IND meeting supports an IND application for RAD 101
- TerThera Terbium-161 isotope supply agreement expanded
- Appendix 4E and FY23 Financial Report
- RAD receives approval for Phase 1 therapeutic study of NSCLC
- FDA green light for diagnostic Phase 1 pancreatic trial
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics